peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

bronchial peptide bioregulator

Chonluten

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

Chonluten is identified in this study as a tripeptide (a peptide made of three amino acids).

Sources for this introduction: [1]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

The abstract states Chonluten’s source as bronchial epithelial cells (cell-type derivation is stated; extraction/purification details are not provided here).

Sources[1]pubmedPeptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.the Chonluten tripeptide, derived from bronchial epithelial cells
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “the Chonluten tripeptide, derived from bronchial epithelial cells”

    Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. · Abstract

    pubmed:35408963:1a39025d612c:1a39025d612c

Identity

Chonluten is identified in this study as a tripeptide (a peptide made of three amino acids).

Sources[1]pubmedPeptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.the Chonluten®tripeptide
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “the Chonluten®tripeptide”

    Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. · Abstract

    pubmed:35408963:1a39025d612c:1a39025d612c

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

Study findings

Under LPS stimulation (a pro-inflammatory bacterial lipopolysaccharide challenge) in vitro, Chonluten is reported to inhibit monocyte TNF production.

Sources[1]pubmedPeptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.the Chonluten tripeptide, derived from bronchial epithelial cells, inhibited in vitro tumor necrosis factor (TNF) production of monocytes exposed to pro-inflammatory bacterial lipopolysaccharide (LPS).
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “the Chonluten tripeptide, derived from bronchial epithelial cells, inhibited in vitro tumor necrosis factor (TNF) production of monocytes exposed to pro-inflammatory bacterial lipopolysaccharide (LPS).”

    Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. · Abstract

    pubmed:35408963:1a39025d612c:1a39025d612c

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, mechanism, regulatory, safety
  • 5 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (5), extraction_ambiguity (5), no_direct_support (5)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. ↗

    pubmed · published 2022-03-25 · retrieved 2026-09-08T21:47:48Z

Publication history and provenance

Version 2 · Automated assessment · 2026-09-08T21:47:48Z

4e6097af1d429ef022d16e903cf4fe55d7c77b300f8a4bd7e299defcf7c8e2c1